In 2019, Novo Nordisk formulated the first oral GLP-1, semaglutide (Rybelsus®) tablet for the treatment of T2DM using sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) as an absorption enhancer using Eligen® technology, developed by Emisphere [100]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.